Tarsus Pharmaceuticals, Inc.

Quick facts

Marketed products

• Lotilaner ophthalmic solution, 0.25% · Ophthalmology
  Lotilaner is a non-selective sigma receptor antagonist that reduces ocular surface inflammation and irritation associated with Demodex mites.

Phase 3 pipeline

• TP-03 · Ophthalmology
  TP-03 is a monoclonal antibody targeting the CD40 receptor.
• TP-03 Vehicle · Ophthalmology
  TP-03 Vehicle is a topical ophthalmic formulation designed to deliver active pharmaceutical ingredients to the ocular surface.

Phase 2 pipeline

• Lotilaner Gel, 2.0%
• TP-03, 0.25%

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Tarsus Pharmaceuticals, Inc. portfolio CI brief
• Tarsus Pharmaceuticals, Inc. pipeline updates RSS